Akebia Therapeutics Inc. (AKBA)
NASDAQ: AKBA
· Real-Time Price · USD
3.24
-0.05 (-1.52%)
At close: Aug 15, 2025, 3:59 PM
3.25
0.31%
After-hours: Aug 15, 2025, 07:55 PM EDT
Akebia Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 6.11M | -22.8M | -20.04M | -8.58M | -17.98M | 613K | -14.49M | -11.83M | -26.22M | -7.55M | -51.87M | 29.28M | -62.42M | -70.68M | -59.54M | -83.04M | -69.58M |
Depreciation & Amortization | 314K | 9.35M | 9.37M | 9.41M | 9.38M | 9.4M | 9.41M | 9.41M | 9.41M | 9.42M | 9.42M | 9.43M | 9.43M | 9.45M | 9.48M | 9.51M | 9.52M |
Stock-Based Compensation | 2.19M | 1.7M | 1.65M | 2.07M | 2.36M | 1.51M | 1.82M | 3.49M | 2.49M | 3.04M | 3.35M | 6.92M | 4.54M | 4.64M | 5.59M | 6.51M | 5.99M |
Other Working Capital | 5.33M | 5.95M | 12.46M | -2.35M | -15.88M | 7.77M | -1.91M | 3.77M | -23.57M | -25.14M | 1.29M | -58.16M | 47.58M | -45.89M | 18.62M | -15.7M | -3.85M |
Other Non-Cash Items | 7.53M | 10.53M | -26.47M | 32.87M | 22.34M | 46.66M | -418K | -1.23M | 616K | -55.67M | 21.19M | -5.79M | 5.57M | 19.84M | -4.06M | 32.29M | -7.07M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -44.3M | 715K | 277K | n/a | n/a | n/a | n/a | n/a | 8.38M | 1.7M | -224K | 26.72M |
Change in Working Capital | -29.73M | -3.23M | 28.79M | -13.64M | -15.15M | -16.21M | -4.21M | 3.52M | -3.83M | -3.92M | 51.7M | -70.49M | 21.27M | -34.44M | -9.45M | -28.19M | -36.33M |
Operating Cash Flow | -13.59M | -4.47M | -6.7M | -10.07M | -19.43M | -2.31M | -7.17M | 3.63M | -17.54M | -54.68M | 33.8M | -30.66M | -21.62M | -62.81M | -56.27M | -63.14M | -70.75M |
Capital Expenditures | -18K | -2K | 29K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -114K | n/a | n/a | n/a | -59K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 20M | 20M |
Other Investing Acitivies | 172K | n/a | -31K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -114K | n/a | n/a | 20M | 20M |
Investing Cash Flow | 154K | -2K | -2K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -114K | n/a | n/a | 20M | 19.94M |
Debt Repayment | 9.54M | 1K | n/a | 7.63M | 274K | -8M | n/a | -8M | -16M | n/a | -33M | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | -63K | n/a | n/a | n/a | -750K | n/a | n/a | n/a | n/a | n/a | n/a | -9K | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 482K | 1.5M | -522K | -736K | 141K | 6.71M | n/a | n/a | n/a | n/a | n/a | 67K | 40M | n/a | n/a | n/a | 74.48M |
Financial Cash Flow | 74.94M | 22.32M | 1.22M | 7.64M | 18.48M | -1.29M | 50K | -8M | -15.97M | -1K | -32.94M | -9K | 47.55M | 5.4M | 16.48M | 37.37M | 74.48M |
Net Cash Flow | 61.51M | 17.86M | -3.81M | -2.46M | -964K | -3.6M | -7.12M | -4.37M | -33.5M | -54.68M | 868K | -30.67M | 25.81M | -57.41M | -39.79M | -5.77M | 23.67M |
Free Cash Flow | -13.61M | -4.47M | -6.67M | -10.1M | -19.43M | -2.31M | -7.17M | 3.63M | -17.54M | -54.68M | 33.8M | -30.66M | -21.73M | -62.81M | -56.27M | -63.14M | -70.81M |